TheraRadar
← Back
Data updated: Jun 28, 2026

SOMERSET THERAPS LLC

Generics

SOMERSET THERAPS LLC is a generic drug manufacturer focused on Cardiovascular, Neurology, Infectious Disease. Key products include POTASSIUM PHOSPHATES.

2008
Since
70
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

SOMERSET THERAPS LLC's Key Drugs

SOMERSET THERAPS LLC's core commercial portfolio centers on CISATRACURIUM BESYLATE PRESERVATIVE FREE, SACUBITRIL AND VALSARTAN, POTASSIUM PHOSPHATES, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.

SOMERSET THERAPS LLC's Therapeutic Areas

SOMERSET THERAPS LLC's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 27%
6 drugs
Neurology 27%
6 drugs
Infectious Disease 23%
5 drugs
Oncology 14%
3 drugs
Metabolic 9%
2 drugs

SOMERSET THERAPS LLC's Top Competitors

SOMERSET THERAPS LLC's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

SOMERSET THERAPS LLC Pipeline Snapshot

Active clinical trials for SOMERSET THERAPS LLC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • CISATRACURIUM BESYLATE PRESERVATIVE FREE leads revenue
  • 3 key drugs tracked

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling